|
Jenex Reports On Progress Towards Canadian Launch
The Jenex Corporation, (TSX-V: JEN) (Frankfurt Exchange: JNX) reports on the progress of bringing their cold sore prevention device to market. Three important steps have been completed. 1.) The cold sore prevention device will be marketed under the name interceptCS. 2.) A final working prototype of the interceptCS device has been completed. 3.) Jenex has received it’s certifications for ISO 9001-2000 and ISO 13485; 2003.
Michael Jenkins, President and CEO of Jenex comments, “The three milestones above are of major significance as we prepare for the launch of our cold sore prevention device. The product name interceptCS was selected after a lengthy review process. We believe the brand name interceptCS will present positively to our Canadian an International markets. We are pleased with the final prototype of interceptCS and feel it has many features that will make usage of the device consumer friendly. The final approval of a working prototype is an essential step towards finalizing arrangements with our manufacturing and distribution partners. We are very pleased to have completed our ISO certification on a timely basis as they will help establish our quality systems and Health Canada requirements for Medical Device marketing. These are important accomplishments and exciting times for Jenex as we prepare to launch our innovative cold sore prevention product.
About The Jenex Corporation:
Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and Europe protect the technology. The Corporation is preparing to launch its cold sore prevention device in the Canadian market in late 2004. Jenex has clearance to market their cold sore prevention device OTC (over-the counter) in Canada, with its approved claim, “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. Regulatory approvals are being pursued for USA, Europe and Australia. It is estimated that there are between 50 and 100 million recurrent cold sore sufferers in North America alone. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market. More information about the Corporation can be found at www.jenexcorp.com.
Forward Looking Statements
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
For further information, please contact:
The Jenex Corporation
Michael Jenkins - President
Phone: 905-632-3830
Email: jenex@sprint.ca
Fax: 905-632-3774
940 Sheldon Court, Suite 207
Burlington, Ontario Canada
L7L 5K6
|
